PP Defence TherapeuticsNews - Page 1

Dr Elias Theodorou joins Defence board of directors

Dr Elias Theodorou is a molecular biologist with over 25 years of experience in the healthcare sector. Read more here.

Defence announces Dr Maxime Parisotto as CSO, Director of Science and Business Development

Dr Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation.

Defence Therapeutics welcomes Dr Svetlana Selivanova to board of directors

Defence Therapeutics has announced that Dr Svetlana Selivanova has joined its board of directors, effective immediately.

Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval

Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project. The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has been approved by...

Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)

Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with...

Defence Therapeutics’ ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...

Innovation News Network - Free Digital eBook Library

Innovation News Network - Global Innovation Partners

Special Reports

Partner News

Special Reports Cont'd

Partner News Cont'd